Pharmaq opens high-tech viral antigen production facility

(12/06/17)

 in Norway

On 1 November 2017, the Norwegian Medicines Agency granted Pharmaq authorisation to produce viral antigens at their new facility in Kløfta.

The site has the capacity to produce several hundred million vaccine doses per annum to be used in Pharmaq’s fish vaccines and will ensure that they have the delivery capacity for the international aquaculture industry for many years to come.

Over 100 guests were invited for the official opening of the facility on 4 December and The Fish Site were one of a handful kindly invited for...................................


Click here to read the rest of this article:
https://thefishsite.com/